Literature DB >> 21057481

What is the value of oncology medicines?

Joshua Cohen1, William Looney.   

Abstract

Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21057481     DOI： 10.1038/nbt1110-1160

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  25 in total

Review 1.  Methodological limitations of cost-effectiveness analysis in health care: implications for decision making and service provision.

Authors:  J Raftery
Journal:  J Eval Clin Pract       Date:  1999-11       Impact factor: 2.431

2.  Public funding of new cancer drugs: Is NICE getting nastier?

Authors:  Anne R Mason; Michael F Drummond
Journal:  Eur J Cancer       Date:  2009-01-08       Impact factor: 9.162

3.  Challenges and opportunities for use of cost-effectiveness analysis.

Authors:  K Robin Yabroff; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2009-08-07       Impact factor: 13.506

4.  Off-label use reimbursement.

Authors:  Joshua Cohen; Andrew Wilson; Laura Faden
Journal:  Food Drug Law J       Date:  2009       Impact factor: 0.619

Review 5.  Preferences, needs and QALYs.

Authors:  J Cohen
Journal:  J Med Ethics       Date:  1996-10       Impact factor: 2.903

6.  A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Authors:  Natasha B Leighl; W Stephen Tsao; Dianne L Zawisza; Mahsan Nematollahi; Frances A Shepherd
Journal:  Lung Cancer       Date:  2005-09-26       Impact factor: 5.705

7.  Toward a comparison of survival in American and European cancer patients.

Authors:  G Gatta; R Capocaccia; M P Coleman; L A Gloeckler Ries; T Hakulinen; A Micheli; M Sant; A Verdecchia; F Berrino
Journal:  Cancer       Date:  2000-08-15       Impact factor: 6.860

8.  Trends in the global funding and activity of cancer research.

Authors:  Seth Eckhouse; Grant Lewison; Richard Sullivan
Journal:  Mol Oncol       Date:  2008-03-27       Impact factor: 6.603

Review 9.  Off-label use of anticancer drugs.

Authors:  Dominique Levêque
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

Review 10.  The person-trade-off approach to valuing health care programs.

Authors:  E Nord
Journal:  Med Decis Making       Date:  1995 Jul-Sep       Impact factor: 2.583
View more
  4 in total

Review 1.  Translational research and the evolving landscape for biomedical innovation.

Authors:  Kenneth I Kaitin
Journal:  J Investig Med       Date:  2012-10       Impact factor: 2.895

2.  "Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?

Authors:  Leonard M Fleck
Journal:  J Pers Med       Date:  2013-07-16

Review 3.  Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

Authors:  Trevor Jozef Piatkiewicz; Janine Marie Traulsen; Tove Holm-Larsen
Journal:  Pharmacoecon Open       Date:  2018-06

Review 4.  Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).

Authors:  Philip Wahlster; Mireille Goetghebeur; Christine Kriza; Charlotte Niederländer; Peter Kolominsky-Rabas
Journal:  BMC Health Serv Res       Date:  2015-07-09       Impact factor: 2.655
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.